Since lung cancer, particularly non-small cell carcinoma is one kind of highly heterogeneous tumors with various genetic expressions, and specific treatment is not always effective to all types of lung cancer [23], we built the hypothesis that different NSCLC cells might exhibit different responses to LDH-A inhibitors. This evidence concerns the gene LDHA and non-small cell lung carcinoma.